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http://dx.doi.org/10.1016/j.stemcr.2016.08.013SUMMARYInduced pluripotent stem cells (iPSCs) are a powerful tool for disease modeling. They are routinely generated from healthy donors and
patients from multiple cell types at different developmental stages. However, reprogramming leukemias is an extremely inefficient
process. Few studies generated iPSCs from primary chronicmyeloid leukemias, but iPSC generation from acutemyeloid or lymphoid leu-
kemias (ALL) has not been achieved. We attempted to generate iPSCs from different subtypes of B-ALL to address the developmental
impact of leukemic fusion genes.OKSM(L)-expressingmono/polycistronic-, retroviral/lentiviral/episomal-, and Sendai virus vector-based
reprogramming strategies failed to render iPSCs invitro and in vivo.Additionof transcriptomic-epigenetic reprogramming ‘‘boosters’’ also
failed to generate iPSCs from B cell blasts and B-ALL lines, and when iPSCs emerged they lacked leukemic fusion genes, demonstrating
non-leukemic myeloid origin. Conversely, MLL-AF4-overexpressing hematopoietic stem cells/B progenitors were successfully reprog-
rammed, indicating that B cell origin and leukemic fusion genewere not reprogramming barriers. Global transcriptome/DNAmethylome
profiling suggested a developmental/differentiation refractoriness of MLL-rearranged B-ALL to reprogramming into pluripotency.INTRODUCTION
Leukemia is generally studied once the full transformation
events have already occurred and, therefore, the mecha-
nisms by which leukemia-specific mutations transform to
a pre-leukemic state followed by rapid transition to overt
leukemia are not amenable to analysis with patient samples
(Ramos-Mejia et al., 2012c). Therefore, it is imperative to
develop effective disease models to study the develop-
mental impact of leukemia-specific genetic aberrations on
human stem cell fate. Induced pluripotent stem cells
(iPSCs) are a powerful tool for modeling different aspects
of human disease that cannot otherwise be addressed by
patient sample analyses or animal models (Menendez
et al., 2006; Wu and Hochedlinger, 2011). Because leuke-602 Stem Cell Reports j Vol. 7 j 602–618 j October 11, 2016 j ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://creativmia manifests as a developmental cell blockage, the gener-
ation and differentiation of leukemia-specific iPSCs offers a
promising strategy to study the earliest events leading to
the specification of both normal and abnormal hemato-
poietic tissue, thus illuminating molecular mechanisms
underlying the pathogenesis of human leukemia.
iPSCs are routinely generated from tissues obtained from
healthy donors and patients and cell types at different
developmental stages. Reprogramming human primary
cancer cells, however, remains challenging. Despite signif-
icant interest in generating iPSCs from leukemia cells
(Curry et al., 2015; Ramos-Mejia et al., 2012c; Yilmazer
et al., 2015), only a few reports have demonstrated success-
ful reprogramming and, unfortunately, only seven of these
studies reprogrammed human primary leukemias (theuthor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
remaining studies used cell lines) (Bedel et al., 2013; Carette
et al., 2010; Gandre-Babbe et al., 2013; Hu, 2014; Kumano
et al., 2012; Yamamoto et al., 2015; Ye et al., 2009) (Table
S1). Intriguingly, iPSCs from hematological primary cancer
cells have exclusively been generated from chronic leuke-
mias of myeloid origin, including Philadelphia+ chronic
myeloid leukemia (CML), primary myelofibrosis (PMF),
JAK2-V617F+ polycythemia vera (PV), and juvenile myelo-
monocytic leukemia (JMML) (Table S1). iPSCs from acute
myeloid leukemia (AML) or acute lymphoid leukemia
(ALL) have not been reported so far, whereas iPSCs have
been generated from normal myeloid and T cells (Bueno
et al., 2016) and, very recently, fromCD19+ B cells fromhu-
man cord blood (CB), peripheral blood (PB), and fetal liver
(FL) using non-integrative tetracistronic OCT4/KLF4/
SOX2/MYC (OSKM)-expressing Sendai virus (SeV) (Bueno
et al., 2016; Munoz-Lopez et al., 2016).
Here, we attempted to reprogram highly fluorescence-
activated cell sorting (FACS)-purified (100% purity) leuke-
mia blasts from three subtypes of B-ALL, t(4;11)/MLL-
AF4+, t(1;11)+MLL-EPS15+, and t(12;21)/ETV6-RUNX1
B-ALL, to establish novel iPSC-based disease models to
address the developmental impact of these leukemia-spe-
cific fusion genes on human stem cell fate. Our data
demonstrate that despite multiple technical and biological
reprogramming strategies, neither primary blasts nor
B-ALL cell lines could be reprogrammed to pluripotency.
Functional assays coupled with global transcriptome and
DNA methylome profiling suggest a developmental/differ-
entiation refractoriness of MLL-rearranged human B-ALL
to reprogramming to pluripotency.RESULTS
Reprogramming B Cell Leukemic Blasts Results in
Generation of iPSCs from Contaminating Normal
Myeloid Cells
iPSCs from primary leukemic cells harboring specific
genetic mutations offer an unprecedented opportunity to
understand how cancer-specific mutations impair tissue
homeostasis by deregulating cell differentiation and
proliferation. We attempted to reprogram blasts from
t(4;11)/MLL-AF4+, t(1;11)+MLL-EPS15+, and t(12;21)/
ETV6-RUNX1+ B-ALL. FACS-purified leukemic blasts
(>99%, Figures 1A and 1B) were infected (or transfected)
with different combinations of monocistronic or polycis-
tronic retroviral, lentiviral, and SeV vectors (or episomal
vectors) expressing either OKSM or OKSL reprogramming
factors (Table 1). No iPSC clones were generated when
reprogramming factors were expressed via episomal vectors
or viral retro-/lentivectors for any of the cytogenetically
different leukemias tested (n = 7, Table 1). iPSC cloneswere exclusively generated when OKSM-expressing SeV
vectors were employed (Figures 1C and 1D; Table 1). How-
ever, all of the resultant clones were negative for the
corresponding fusion gene at the genomic (fluorescent
in situ hybridization [FISH] and PCR) and RNA (RT-PCR)
level (Figures 1E and 1F; Table 1).
Several molecules that promote or enhance reprogram-
ming, so-called reprogramming ‘‘boosters,’’ have been re-
ported (Esteban et al., 2010; Goyal et al., 2013; Onder
et al., 2012; Soria-Valles et al., 2015; Zhang and Wu,
2013). SeV-OKSM-mediated reprogramming experiments
were performed (mainly with MLL-AF4+ B-ALL blasts)
using many reprogramming epigenetic/transcriptomic
factors described to improve reprogramming (Hu, 2014;
Lin and Wu, 2015). Although some of these factors
enhanced the reprogramming efficiency (Figure 1G), FISH
and RT-PCR assays revealed the absence of the fusion
gene in resulting clones, indicating that residual non-
leukemic myeloid cells were reprogrammed to pluripo-
tency (Table 1). Furthermore, healthy adult B cells are
known to be difficult to reprogram.We therefore attempted
to reprogram MLL-AF4+ B cell blasts using SeV-OKSM in
combination with (1) compounds which specifically target
MLL fusion-driven signaling such as the Dot1L inhibitor
and an inhibitor of Menin-MLL interaction (He et al.,
2016) (2) the lymphoid ‘‘path breaker’’ cEBPa (Bueno
et al., 2016; Di Stefano et al., 2014), or (3) phosphatase
and tensin homolog (PTEN) inhibitors that constitutively
activate the phosphoinositol 3-kinase (PI3K) pathway re-
sulting in increased iPSC generation (Liao et al., 2013)
and rescue of B cell receptor (BCR)-defective B cells (Sriniva-
san et al., 2009). Although these conditions rendered iPSC
clones, they were consistently negative for theMLL fusions
(Table 1; Figures S1A and S1B). Importantly, OKSM-SeV-
mediated reprogramming, with or without additional re-
programming boosters, of MLL-AF4+ leukemic blasts after
double FACS sorting (virtually 100% purity) rendered no
iPSC colonies, indicating that the limited number of iPSC
clones lacking the MLL fusion were derived from easy-to-
reprogram residual/contaminating non-leukemic myeloid
cells (Table 1).
Immortalized B Cell Lines and Xenograft-Expanded
Proliferating MLL-AF4+ Leukemic Blasts Are
Refractory to Reprogramming to Pluripotency
Because human acute leukemias do not proliferate in vitro,
we hypothesized that successful iPSC generation from
leukemic blasts would rely on our ability to induce their
proliferation. As a first approach, we used human leukemic
B cell lines derived from B-ALL patients with MLL rear-
rangements (SEM and THP1) or with ETV6-RUNX1
(REH), rather than non-proliferating primary blasts. To
this end, B cell lines were infected with OKSM-, OKSL-, orStem Cell Reports j Vol. 7 j 602–618 j October 11, 2016 603
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Figure 1. Reprogramming Highly Purified B Cell Leukemic Blasts Results in Generation of iPSCs from Contaminating Normal
Myeloid Cells
(A) Representative flow cytometry of high purity (>99%) FACS-sorted B cell leukemia blasts.
(B) Representative FISH showing that leukemia blasts homogeneously harbor the leukemia-specific chromosomal rearrangements 11q23
(MLL) or ETV6-RUNX1 (white arrows). Scale bars, 5 mm.
(C) Scheme of the polycistronic SeV-OKSM-mir302 vector used for reprogramming.
(D) Scheme of the strategy used to reprogram leukemia blasts.
(E) Resulting iPSC colonies do not harbor either MLL or ETV6-RUNX1 rearrangements. Scale bars, 5 mm.
(F) Genomic PCR confirming the absence of both MLL and ETV6-RUNX1 in resulting iPSC colonies.
(G) Representative experiment (n = 1) showing that factors such as sodium salicylate (NaS), decitabine, and iDot1L enhance the
reprogramming of contaminating cells lacking either MLL or ETV6-RUNX1 rearrangements (n = 3).
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Table 1. Summary of the Reprogramming Conditions Used in This Study and Their Outcome
Reprogramming Factors Additional Factors
B-ALL
t(4;11)
B-ALL
t(1;11)
B-ALL
t(12;21)
Sort Purity
(No. of Sorts) Clones
iFISH for
MLL Locus
PCR for
MLL Fusion
Lentiviral OKSM
polycistronic
None O O O R99% (single) 0 NA NA
ascorbic acid O ND ND R99% (single) 0 NA NA
sodium butyrate O ND ND R99% (single) 0 NA NA
valproic acid O ND ND R99% (single) 0 NA NA
LiCl O ND ND R99% (single) 0 NA NA
pLVX-mir302 O O O R99% (single) 0 NA NA
Episomal OKSM none O O O R99% (single) 0 NA NA
ascorbic acid O ND ND R99% (single) 0 NA NA
sodium butyrate O ND ND R99% (single) 0 NA NA
valproic acid O ND ND R99% (single) 0 NA NA
LiCl O ND ND R99% (single) 0 NA NA
pLVX-mir302 O O O R99% (single) 0 NA NA
Episomal OKSL none O O O R99% (single) 0 NA NA
pLVX-mir302 O O O R99% (single) 0 NA NA
Retroviral OKSM none O O O R99% (single) 0 NA NA
SeV-OKSM none O O O R99% (single) yes* negative negative
SeVdp-OKSM polycistronic none O O O R99% (single) yes* negative negative
sodium salicylate O O O R99% (single) yes* negative negative
decitabine O ND ND R99% (single) yes* negative negative
iDot1L (SGC0946) O ND ND R99% (single) yes* negative negative
iDot1L (epz004777) O ND ND R99% (single) yes* negative negative
iMenin-MLL (iML2) O ND ND R99% (single) yes* negative negative
ectopic c/EBPa O ND ND R99% (single) yes* negative ND
iPTEN (bVp(HO)pic) O ND ND R99% (single) yes* negative ND
c/EBPa + iPTEN O ND ND R99% (single) yes* negative ND
decitabine O ND ND 100% (double) 0 NA NA
trichostatin A O ND ND 100% (double) 0 NA NA
valproic acid O ND ND 100% (double) 0 NA NA
sodium butyrate O ND ND 100% (double) 0 NA NA
iSUV39H1 (Chaetocin) O ND ND 100% (double) 0 NA NA
iEZH2 (GSK126) O ND ND 100% (double) 0 NA NA
iEZH2 (DZNep) O ND ND 100% (double) 0 NA NA
iBRD4 (JQ1) O ND ND 100% (double) 0 NA NA
iCDK-P-TEFb (flavopiridol) O ND ND 100% (double) 0 NA NA
(Continued on next page)
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Table 1. Continued
Reprogramming Factors Additional Factors
B-ALL
t(4;11)
B-ALL
t(1;11)
B-ALL
t(12;21)
Sort Purity
(No. of Sorts) Clones
iFISH for
MLL Locus
PCR for
MLL Fusion
ascorbic acid O ND ND 100% (double) 0 NA NA
octyl-a-ketoglutarate O ND ND 100% (double) 0 NA NA
shRing1a MOI = 10 O ND ND 100% (double) 0 NA NA
shMacroH2A MOI = 10 O ND ND 100% (double) 0 NA NA
OKSM, Oct4, Klf4, Sox2, Myc; OKSL, Oct4, Klf4, Sox2, Lin28; SeVdp, Sendai vector-defective persistent; ND, not done; NA, not applicable; yes*, the number of
clones varies between 5 and 50.OKSML-expressing SeV vectors alone or in combination
with epigenetic and transcriptomic reprogramming
boosters; however, no iPSC clones could be generated (Fig-
ure S2A and Table 2). Moreover, immortalized B cell lines
primed with decitabine and trichostatin A (TSA) prior to
OKSM-SeV infection and then exposed to the aforemen-
tioned additional chemical inducers, also failed to generate
iPSC clones (Figure S2B and Table 2). In another approach,
SEM cells were stably knocked down for genes reported to
act as barriers to induced pluripotency prior to OKSM-SeV
infection (Gaspar-Maia et al., 2013; Menendez et al.,
2010; Nashun et al., 2015; Pasque et al., 2011). Intriguingly,
small hairpin RNA (shRNA)-mediated knockdown of the
tumor suppressor p53, themaster B cell transcription factor
Pax5, the Polycomb protein RING1a, and the histone
variant macroH2A1 failed to facilitate the generation of
iPSCs (Table 2; Figures S1C and S1D). Combination of
p53 knockdown with 7 days’ treatment with demethylat-
ing agents (5-azacytidine, decitabine) before and after
OKSM infection also failed to generate iPSCs. The knock-
down of macroH2A1 was shown to reactivate a reporter
gene on the inactive X chromosome only when combined
with decitabine and TSA (Hernandez-Munoz et al., 2005).
As reactivation of the inactive X is a hallmark of reprogram-
ming (Ohhata and Wutz, 2013), we tested the same and
other triple combinations but found that SEM cells
remained resistant to OKSM-induced reprogramming
(Table 2).
We next induced primary blasts to proliferate through
xenograft expansion. Two approaches were followed: (1)
in vivo expansion of OKSM-SeV-infected primary B cell
blasts or (2) OKSM-SeV infection of in vivo expanded pri-
mary B cell blasts. In the second scenario, engrafted mice
were treated with iDoT1L, decitabine, or left untreated, to
(epi)-genetically prime the blasts prior to OKSM-SeV-infec-
tion (Figure 2A). Although these strategies generated some
iPSC clones after in vivo expansion of primary blasts in
xenograftedmice, all iPSCs analyzed lacked theMLL fusion
gene by FISH and PCR, and were of mouse origin (Figures
2A and 2B). Together these results show that in vivo606 Stem Cell Reports j Vol. 7 j 602–618 j October 11, 2016expanded leukemic blasts consistently failed to be
reprogrammed.
MLL-AF4 Expression by Itself Is Not a Reprogramming
Barrier
Our results show that neither primary MLL-AF4+ blasts
nor proliferating leukemic B cell lines can be reprog-
rammed. However, and in line with previous work
(Munoz-Lopez et al., 2016), Epstein-Barr virus (EBV)-
immortalized healthy B cells as well as healthy pro-B
and pre-B cells could be successfully reprogrammed (Fig-
ure S2C), suggesting that the leukemia-initiating event
(e.g., MLL fusion genes) may represent a reprogramming
barrier. To test this idea, we lentivirally transduced both
CB-CD34+ hematopoietic stem/progenitor cells (HSPCs)
and CD34+CD19+ B cell progenitors with MLL-AF4-GFP,
and after several days infected MLL-AF4-expressing
CD34+ and CD34+CD19+ cells with OKSM-SeV (Bueno
et al., 2015). MLL-AF4 expression did not impair the gen-
eration of iPSCs, and the reprogramming efficiency was
similar to that of GFP-transduced CD34+ HSPCs (Fig-
ure 3A) and CD34+CD19+ B cell progenitors (Figure S3A).
Resulting iPSC clones displayed human embryonic stem
cell (hESC)-like morphology and expressed MLL-AF4-
GFP (Figures 3B and S3B). Further characterization re-
vealed that MLL-AF4 was present in the majority of the
iPSC clones and was always expressed (Figures 3C, 3D,
and S3B) after ten passages. In addition, MLL-AF4-express-
ing iPSC clones were OKSM transgene independent (Fig-
ure 3E), diploid (Figure 3F), positive for alkaline phospha-
tase (Figure 3G), and expressed the pluripotency factors
NANOG, OCT4, SOX2, REX1, DNMT3b, and CRIPTO (Fig-
ure 3H) and the surface markers TRA-1-60, SSEA3,
and SSEA4 (Figure 3I). Importantly, iPSCs derived from
MLL-AF4-expressing CD34+CD19+ B cell progenitors
carried complete VDJH immunoglobulin gene mono-
clonal rearrangements, confirming the B lineage identity
(Figure S3C). Collectively, these results suggest that
MLL-AF4 expression does not seem to represent a re-
programming barrier in either CD34+ cells or CD34+
Table 2. Summary of the Conditions Used to Reprogram the Leukemic B Cell Lines SEM, THP1, and REH
Reprogramming Factors Additional Factors SEM t(4;11) THP1 t(9;11) REH t(12;21) Clones iFISH Genomic PCR
SeVdp-OSKM polycistronic none O O O no NA NA
shp53 (MOI = 10) O O O no NA NA
shPax5 (MOI = 10) O O O no NA NA
cEBPa (MOI = 10) O O O no NA NA
ShRING1a (MOI = 10) O ND ND no NA NA
shMacroH2A1 (MOI = 10) O ND ND no NA NA
iPTEN (bVp(HO)pic) O O O no NA NA
decitabine O ND ND no NA NA
iDot1L (SGC0946) O ND ND no NA NA
iDot1L (epz004777) O ND ND no NA NA
iMenin-Dot1L (iML2) O ND ND no NA NA
trichostatin A O ND ND no NA NA
valproic acid O ND ND no NA NA
sodium butyrate O ND ND no NA NA
sodium salicylate O ND ND no NA NA
iSUV39H1 (Chaetocin) O ND ND no NA NA
iEZH2 (GSK126) O ND ND no NA NA
iEZH2 (DZNep) O ND ND no NA NA
iBRD4 (JQ1) O ND ND no NA NA
iCDK/iP-TEFb (Flavopiridol) O ND ND no NA NA
ascorbic acid O ND ND no NA NA
octyl-a-ketoglutarate O ND ND no NA NA
SeVdp-OSKL polycistronic none O O O no NA NA
SeVdp-OSKLN polycistronic none O O O no NA NA
SeVdp-OSKM polycistronic +
decitabine 0.1 mM +
trichostatin A 2 mM
none O O O no NA NA
shRING1a MOI = 10 O ND ND no NA NA
shMacroH2A1 MOI = 10 O ND ND no NA NA
iDot1L (SGC09469) O ND ND no NA NA
iDot1L (epz004777) O ND ND no NA NA
iMenin-MLL (iML2) O ND ND no NA NA
valproic acid O ND ND no NA NA
sodium butyrate O ND ND no NA NA
sodium salicylate O ND ND no NA NA
iSUV39H1 (Chaetocin) O ND ND no NA NA
(Continued on next page)
Stem Cell Reports j Vol. 7 j 602–618 j October 11, 2016 607
Table 2. Continued
Reprogramming Factors Additional Factors SEM t(4;11) THP1 t(9;11) REH t(12;21) Clones iFISH Genomic PCR
iEZH2 (GSK126) O ND ND no NA NA
iEZH2 (DZNep) O ND ND no NA NA
iBRD4 (JQ1) O ND ND no NA NA
iCDK/iP-TEFb (flavopiridol) O ND ND no NA NA
ascorbic acid O ND ND no NA NA
octyl-a-ketoglutarate O ND ND no NA NA
ND, not done; NA, not analyzed.CD19+ B cell progenitors, and is compatible with
pluripotency.Global Transcriptome and DNA Methylome Analyses
Suggest a Developmental Refractoriness of MLL-
Rearranged B-ALL to Reprogramming to Pluripotency
To identify patterns of gene expression that might provide
a molecular explanation for the refractoriness of leukemic
blasts to reprogramming, we compared gene expression
profiles of FACS-purified MLL-AF4+ blasts from infant
B-ALL (n = 3) with hematopoietic stem cells (HSCs)
(n = 2), B cell hematopoietic progenitor cells (HPCs)
(n = 2), and myeloid HPCs (n = 2) from healthy CB. A
heatmap representation of hierarchical clustering of genes
differentially expressed (2-fold regulated; p < 0.01) in
MLL-AF4+ blasts versus healthy HSPCs is shown in Fig-
ure 4A. A total of 87 genes were differentially expressed
in MLL-AF4+ blasts (Figures 4B and 4C). To gain insight
into the biological functions affected by differentially ex-
pressed genes, we performed gene ontology (GO) analysis
comparing MLL-AF4+ blasts with normal HSPCs (Fig-
ure 4D). Among the top significant GO biological
processes enriched in MLL-AF4+ blasts, we found ‘‘cell
differentiation,’’ ‘‘cell morphogenesis,’’ ‘‘developmental
process,’’ and ‘‘cell proliferation’’ (Figure 4C), suggesting
that the intrinsic developmental (differentiation)
blockage and proliferative defects of leukemic blasts,
rather than leukemia-specific genetic alterations, may
constitute a reprogramming barrier.
Similarly, to identify potential DNA methylation
changes explaining the refractoriness of leukemic blasts
to reprogramming, we performed global DNA methyl-
ation (LINE-1) profiling on FACS-purified MLL-AF4+ blasts
from infant B-ALL (n = 3), B cell HPCs (n = 2), and MLL-
AF4-expressing CD34+ HSPCs. Although no major quanti-
tative changes in global DNA methylation were revealed
by bisulfite pyrosequencing (Figure 5A), DNA methylation
450K BeadChip arrays identified 6,700 CpG sites differ-
entially methylated (dmCpGs; false discovery rate <0.05)608 Stem Cell Reports j Vol. 7 j 602–618 j October 11, 2016between MLL-AF4+ blasts and both B cell HPCs and
MLL-AF4-expressing HSPCs (Figures 5B and 5C). Specif-
ically, 1,691 dmCpGs were hypomethylated and 5,012
CpGs hypermethylated in MLL-AF4+ leukemic blasts
(Figure 5C). GO analysis of hypermethylated dmCpGs re-
vealed ‘‘cell differentiation,’’ ‘‘cell morphogenesis,’’ and
‘‘developmental process’’ as significant biological pro-
cesses enriched in MLL-AF4+ blasts (Figure 5D). GO
analysis of hypomethylated dmCpGs identified RAS/JAK-
STAT/MAPK activities (through which BCR-mediated
signaling regulates B cell activation and differentiation)
(Marshall et al., 2000) as significant biological processes
enriched in MLL-AF4+ blasts (Figure 5D). Thus, in line
with the transcriptome data, these results suggest that
the intrinsic differentiation blockage and proliferative
status of leukemic blasts constitute a bona fide reprogram-
ming barrier.DISCUSSION
iPSCs reprogrammed from cancer cells have the potential
to illuminate molecular mechanisms underlying the path-
ogenesis of cancer (Barrett et al., 2014; Curry et al., 2015;
Ramos-Mejia et al., 2012c; Yilmazer et al., 2015). However,
reprogramming human primary cancer cells remains
challenging, and only a few reports have demonstrated
successful reprogramming of malignant cells. Moreover,
iPSCs from primary leukemic cells have exclusively been
generated from chronic hematological malignances,
including Philadelphia+ CML, PMF, JAK2-V617F+ PV, and
JMML (Bedel et al., 2013; Carette et al., 2010; Gandre-
Babbe et al., 2013; Hu, 2014; Kumano et al., 2012; Yama-
moto et al., 2015; Ye et al., 2009) (Table S1). No iPSCs
reprogrammed from acute leukemias have been reported,
but iPSCs have been successfully generated from normal
myeloid, T cells, and B cells using non-integrative tetracis-
tronic OKSM-expressing SeV (Bueno et al., 2016; Munoz-
Lopez et al., 2016). Here, we attempted to establish an
iPSC-based disease model to address the developmental
CD45-FITC
Purity > 99%
CD
19
-P
E
Blast purifica on
SeV Infec on
(MOI:3)
In vivo expansion
of infected blasts
5-8 wks
Ex vivo teratoma
disaggrega on
ESCs culture 
condi ons
hu-βActin mo-GAPDH hu-MLLAF4
 1 32 4  1 32 4  1 32 4
In vivo expansion
of blasts
105
105
105
105
100
100
100
100
huHLA-ABC-FITC
hu
CD
45
-A
PCTreatment of 
ENGRAFTED mice
iDOT1L
Decitabine
SeV Infec on
(MOI:3)
Ex vivo blast 
purifica on iPSC emergence
iPSC emergence
Analysis (FISH/PCR)
Analysis (PCR)
Reprogramming condi ons of xenogra -expanded primary blasts
Reprogramming 
Factors
Addi onal
Factors
SeVdp-OKSM
polycistronic
B-ALL
t(4:11) Clones
iFISH for 
MLL locus
gDNA
for MLL fusion
None
Decitabine*
iDot1L (epz-4777)*
*2.5mg/kg in vivo
YES (10)
YES (550)
√
√
√ YES (10)
Nega ve/Murine
Nega ve/Murine
Nega ve/Murine
Nega ve/Murine
Nega ve/Murine
Nega ve/Murine
A
B
5-8 wks
10x
Figure 2. Reprogramming of Xenograft-Expanded Proliferating Highly Purified MLL-AF4+ Leukemic Blasts Results in Generation of
iPSCs from Contaminating Mouse Cells
(A) Schematic depicting the in vivo strategies used to reprogram proliferating xenograft-expanded MLLr leukemic blasts. MLL-AF4+ blasts
were either first OKSM-infected and then xenografted for proliferation (‘‘expand infected blasts’’) or xenografted first for proliferation (and
treated in vivo with decitabine or iDot1L), then OKSM infected ex vivo (‘‘infect expanded blasts’’).
(B) Summary of the outcome of reprogramming in vivo xenografted MLL-AF4+ blasts (n = 2 independent experiments).impact of leukemia-specific fusion genes on human stem
cell fate. We provide insights into the difficulty of reprog-
ramming primary leukemia blasts from cytogenetically
different subtypes of B-ALL, including t(4;11)/MLL-AF4+,
t(1;11)+MLL-EPS15+, and t(12;21)/ETV6-RUNX1 B-ALL.
Our data demonstrate that neither primary blasts nor
B-ALL cell lines could be reprogrammed to pluripotency.
The few iPSC clones that were generated consistently
lacked the leukemic fusion gene, indicating that only resid-
ual/contaminating non-leukemic myeloid cells, which are
less demanding to reprogram than lymphoid cells, were re-
programmed (Bueno et al., 2016).
The question remains open as to whether biological or
technical reprogramming barriers underlie the inability of
B-ALL leukemic blasts to be reprogrammed. Technically,multiple reprogramming strategies were attempted, but
neither transient nor stable expression of reprogramming
factors using a variety of monocistronic and polycistronic
vectors rendered leukemic iPSCs. The choice of reprogram-
ming factors (OKSM, OKSL, or OKSML) also had little
impact on the reprogramming outcome, suggesting that
the methods used for transgene delivery and c-myc depen-
dency are not causal mechanisms responsible for the lack
of success. From a biological standpoint, cell identity is a
reflection of cell-type-specific gene expression and epige-
netic signatures. A variety of transcription factors, tumor
suppressors, microRNAs, and chromatin-remodeling en-
zymes, as well as chemical regulators of histone and DNA
modifications, have been extensively reported to provide
a permissive environment for cell-fate change duringStem Cell Reports j Vol. 7 j 602–618 j October 11, 2016 609
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Figure 3. MLL-AF4 Expression Does Not Constitute a Reprogramming Barrier on Its Own
(A) Representative TRA-1-60 staining of iPSC colonies generated from CB-CD34+ HSPCs ectopically expressing GFP alone (empty vector; EV) or
MLL-AF4 (n = 3 independent experiments). No iPSC colonies were obtained from SEM, THP1, or REH cell lines (n = 3 independent experiments).
(legend continued on next page)
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cellular reprogramming (Nashun et al., 2015). We com-
bined different reprogramming strategies with several re-
programming ‘‘boosters’’ acting on transcription factor
expression and chromatin structure; yet, iPSCs could not
be generated. Recently, the differentiation blockage of
BCR-ABL1+ B cell ALL cells was overcome by forcing cells
to reprogram to the myeloid lineage through exposure to
myeloid differentiation-promoting cytokines in vitro or
by transient expression of the myeloid transcription factor
C/EBPa (McClellan et al., 2015). Similarly, mouse and hu-
man healthy B cells were efficiently reprogrammed upon
C/EBPa-mediated myeloid priming (Bueno et al., 2016; Di
Stefano et al., 2014). Unfortunately, neither C/EBPa expres-
sion (Tables 1 and 2) nor exposure to myeloid differentia-
tion-promoting cytokines (interleukin-3 [IL-3], IL-6, FLT3,
granulocyte macrophage colony-stimulating factor, and
macrophage colony-stimulating factor; data not shown)
sensitized MLL-AF4+ blasts to undergo myeloid priming
and subsequent reprogramming.
Active cell proliferation is key for transcription factor-
induced cell-fate change during cellular reprogramming.
Because acute leukemias barely or do not proliferate
in vitro, we endeavored to reprogram leukemic B cell lines
as well as MLL-rearranged primary blasts induced to pro-
liferate through xenograft expansion. Again, these ap-
proaches consistently failed to reprogram in vivo expanded
leukemic blasts; only somemurine iPSCs were generated as
a result of traces of OKSM-SeV carry-over after in vivo trans-
plantation. However, EBV-immortalized healthy B cells as
well as healthy pro-B and pre-B precursors could be success-
fully reprogrammed (Munoz-Lopez et al., 2016), suggesting
that the leukemia-initiating genetic event might represent
a reprogramming barrier. However, functional data proved
thatMLL-AF4 expression in both CB-derived CD34+ HSPCs
and CD34+CD19+ B cell progenitors was compatible with
pluripotency and did not impede reprogramming, indi-
cating that the leukemia driver genetic event does not itself
represent a barrier.
Cell-type-specific gene expression profiles and specific
chromatin signatures establish epigenetic barriers to tran-
scription factor-mediated reprogramming. Consequently,
global transcriptome and DNA methylome analyses were(B) Phase-contrast and fluorescence images of iPSC colonies gener
100 mm.
(C) Genomic PCR revealing that 85% of the iPSCs harbor MLL-AF4 p
(D) RT-PCR revealing that all iPSC clones carrying MLL-AF4 provirus e
(E) Representative qRT-PCR demonstrating SeV elimination after ten
(F) Representative diploid karyotype of iPSCs (p15) derived from MLL
(G) Representative morphology and alkaline phosphatase staining of
(H) qRT-PCR for the pluripotency transcription factors OCT4, SOX2, NA
(I) Representative flow cytometry expression of the pluripotency-asso
iPSCs.performed to gain insight into the refractoriness of
leukemic blasts to reprogramming. Our data suggest a
developmental refractoriness of MLL-rearranged B-ALL to
reprogramming to pluripotency, reflecting that the
intrinsic differentiation blockage of leukemic blasts consti-
tutes a bona fide reprogramming barrier. In addition, anal-
ysis of hypomethylated dmCpGs identified RAS/JAK-STAT/
MAPK signaling to be likely involved in refractoriness to
reprogram MLL-AF4+ blasts (Figure 5D). These pathways
are master signaling effectors of BCR-mediated signaling
regulation of B cell activation and differentiation (Marshall
et al., 2000). However, chemical activation of the PI3K-
AKT-Ras pathway (through PTEN inhibition), which can
rescue BCR-defective B cells (Srinivasan et al., 2009), failed
to reprogram primary B-ALL blasts/cell lines. In line with
the transcriptome data, we suggest that the intrinsic differ-
entiation blockage and proliferative status of leukemic
blasts constitutes a bona fide reprogramming barrier.
Recent studies on the 3D chromosome regulatory land-
scape of human pluripotent stem cells have revealed the
importance of chromosome structure and topologically
associating domains in maintaining pluripotency (Ji
et al., 2016). In addition, an elegant study has suggested
that some large genetic rearrangements (e.g., ring chromo-
somes) are not compatible with the pluripotent state, likely
due to the inability of establishing the characteristic chro-
mosomal topology of iPSCs (Bershteyn et al., 2014).
Whether genetically complex leukemic chromosomal
translocations impede leukemic blast reprogramming
cannot be ruled out. In addition, these genetic rearrange-
ments may simply be lethal in a pluripotent cell context.
Preliminary data from our laboratory suggest that after
generating a t(4;11)/MLL-AF4+ translocation in human
iPSCs using the CRISPR/Cas9 system (Torres et al., 2014),
t(4;11)-carrying clones are lost after a few passages, suggest-
ing that large genetic rearrangements may not be compat-
ible with pluripotency. Further work is needed to identify
and overcome the biological barriers impeding reprogram-
ming of acute leukemias and primary cancer cells, which
may reveal information on the links between pluripotency
and oncogenic transformation that would be instrumental
for the development of new therapies.ated from EV- and MLL-AF4-expressing CB-CD34+ cells. Scale bar,
rovirus.
xpress MLL-AF4 transcript.
passages.
-AF4-expressing CD34+ cells.
iPSCs derived from MLL-AF4-expressing CD34+ cells.
NOG, REX1, CRIPTO, and DNMT3b in MLL-AF4+ iPSCs.
ciated surface markers TRA-1-60, SSEA-3, and SSEA-4 by MLL-AF4+
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Figure 4. Gene Expression Profiling Comparing MLL-AF4+ B Cell Blasts with HSCs, Myeloid HPCs, and B Cell HPCs
(A) Heatmap depicting the genes differentially expressed (2-fold up- or downregulated; p < 0.01) in MLL-AF4+ B cell blasts versus normal
HSCs and HPCs. The left color bar categorizes the gene expression level in a log2 scale.
(B) Venn diagrams showing the number of transcripts differentially expressed between MLL-AF4+ blasts and HSCs, B cell HPCs, and
myeloid HPCs.
(legend continued on next page)
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EXPERIMENTAL PROCEDURES
Primary Leukemic Samples, Normal HSC/HPCs,
EBV-Immortalized B Cells, and Leukemic Cell Lines
Human primary B cell leukemic samples, and CB- and FL-derived
HSPCs were obtained in accordance with procedures approved
by the Clinic Hospital of Barcelona or the Erasmus University
Medical Center in Rotterdam. Informed consent was obtained in
accordance with the Declaration of Helsinki. B cell leukemias
used corresponded to the following cytogenetic subtypes:
t(4;11)/MLL-AF4+ (n = 4), t(1;11)/MLL-EPS15+ (n = 2), and t(12;
21)/ETV6-RUNX1+ (n = 2). Primary leukemias with >80% of blasts
were processed as reported previously (Bueno et al., 2014; Menen-
dez et al., 2009). In brief, after Ficoll-based gradient centrifugation,
mononuclear cells were stained with anti-human CD45 (555482,
Beckton Dickinson), CD34 (130-081-001, Miltenyi), CD19 (130-
091-328, Miltenyi), and CD10 (555376, Becton Dickinson). Live
(7AAD) blast cells (CD45dimCD19+) were highly purified using a
FACSAria-III sorter (Becton Dickinson, Figure 1A). A one- or two-
round sorting strategy was used as indicated with resulting purities
>99% and practically 100%, respectively (Figure 1A and Table 1).
CB-derived CD34+ HSPCs and FL-derived CD34+CD19+ B cell
HPCs were processed as described previously (Bueno et al., 2015;
Munoz-Lopez et al., 2016; Prieto et al., 2016; Ramos-Mejia et al.,
2012d). Where indicated, CD34+ cells were lentivirally transduced
withMLL-AF4-GFP as reported (Montes et al., 2014) andMLL-AF4-
GFP-expressing CD34+ cells were FACS enriched for iPSC genera-
tion and DNA methylome studies (see below). SEM (MLL-AF4+),
THP1 (MLL-AF9+), and REH (ETV6-RUNX1+) B cell lines were
grown in DMEM + 10% fetal bovine serum (FBS) + 1% P/Sas as
described by Bueno et al. (2008). A lymphoblastoid B cell line
was obtained from the Spanish National DNA Bank (Salamanca).
This cell line was established by immortalizing PB B cells of a
healthy female donor with EBV. Culture conditions were RPMI +
GlutaMAX+ 15% FBS + 1%penicillin-streptomycin (Munoz-Lopez
et al., 2016).
Vectors, iPSC Generation, and Characterization
Human primary leukemias were infected with OKSM(L)-express-
ing vectors immediately after FACS sorting. The following vectors
were used: (1) OKSM polycistronic lentivector, (2) OKSM or OKSL
non-integrative monocistronic episomal vectors, (3) OKSMmono-
cistronic retroviral vectors, (4) OKSM monocistronic SeV vector,
and (5) OKSM polycistronic SeV vectors (Bueno et al., 2016; Mu-
noz-Lopez et al., 2016) (Table 1). Primary HSPCs, EBV-immortal-
ized B lymphocytes, and in vivo expanded blasts were infected
with OKSM polycistronic SeV vector immediately after FACS sort-
ing. Wild-type and shRNA-knockdown (KD) SEM, THP1, and REH
cell lines were transduced with OKSM, OKSL, or OKSML polycis-
tronic SeV vector after 3 days of priming with reprogramming
factors (Figure S2A and Table 2) or decitabine + TSA (Figure S2B(C) Identification of the 87 genes shared by normal HSC, B cell HPCs, an
and blue identify upregulated and downregulated genes, respectively
(D) Statistically significant GO biological functions identified using
blasts versus normal HSCs/HPCs ranked p value.log p value, black ba
y axis).and Table 2). KD B cell lines were generated using shRNA-express-
ing pLKO-based lentiviral vectors for P53, PAX5, RING1a, andmac-
roH2A1 as described previously (Ramos-Mejia et al., 2014; Real
et al., 2012). cEBPa was ectopically expressed using a cEBPa-ex-
pressing SeV vector previously generated in our laboratory (Bueno
et al., 2016; Di Stefano et al., 2014). SeV vectors, lenti-/retrovectors,
and shRNA-expressing pLKO lentivectors were used at MOI of 3–4,
5–10, and 10, respectively (Figure 1 and Table 2). OKSM-infected
human primary cells (5 3 105 per experiment) and SEM/THP1/
REH cell lines were stimulated/maintained with 10%–20% FBS
supplemented with either the hematopoietic cytokines IL-7, IL-3,
SCF, FLT3L, and TPO (Bueno et al., 2016; Munoz-Lopez et al.,
2016) or reprogramming factors. Cells were plated onto irradiated
mouse embryonic fibroblasts (MEFs) for 3 days without a medium
change and were thereafter maintained on MEF-conditioned me-
dium supplemented with 8 ng/mL basic fibroblast growth factor
(bFGF) (Miltenyi Biotec)withmediumchanges every other day un-
til iPSC colonies emerged (Bueno et al., 2016; Munoz-Lopez et al.,
2016). Identification of the first emerging iPSC colonies (6–8 days
after OKSM infection) and passage onto fresh feeders was doneme-
chanically as described. Depending on the reprogramming condi-
tions, iPSC colonies were established by days 18–30, and were
immunostained for TRA-1-60 to determine the reprogramming ef-
ficiency. iPSC clones were further maintained on irradiated MEFs
in hESC medium supplemented with 8 ng/mL bFGF. hESC me-
dium was changed daily, and the colonies were passaged mechan-
ically weekly (Montes et al., 2009; Ramos-Mejia et al., 2012b).
Established iPSCs were characterized as previously described in
detail (Bueno et al., 2016; Munoz-Lopez et al., 2016) upon confir-
mation of their bona fide morphology and transgene indepen-
dency. Each iPSC clone was analyzed beforehand for the presence
of the chromosomal rearrangement by FISH (see below), genomic
PCR, andRT-PCR, using standard procedures and primers shown in
Table S2. SeV elimination was determined by qRT-PCR. Expression
of pluripotency markers was performed by alkaline phosphatase
and TRA-1-60 immunostaining, by qRT-PCR for OCT4, NANOG,
SOX2, REX1, CRIPTO, and DNMT3B, and by flow cytometry using
anti-human SSEA-3 (560237), SSEA-4 (561156), and TRA-1-60
(563188) antibodies (BecktonDickinson). Primers and flow cytom-
etry antibodies used are shown in Table S2. Normal karyotype was
confirmed by conventional G banding (Catalina et al., 2008).
Expansion of Leukemic Blasts in NSG Mice and iPSC
Generation
Human acute leukemias barely or do not proliferate in vitro. In an
attempt to enhance the efficiency of iPSC generation from
leukemic blasts, primary leukemias were intratibia-transplanted
in NSG mice and allowed to proliferate in vivo. MLL-AF4+ blasts
were (1) OKSM infected, in vivo expanded, and then retrieved
and plated for iPSC emergence (‘‘expand infected blasts’’) or (2)
in vivo expanded, retrieved by FACS sorting, OKSM infected, andd myeloid HPCs but differentially expressed in MLL-AF4+ blasts. Red
.
GOrilla software of the genes differentially expressed in MLL-AF4+
rs (left y axis); enrichment score, filled red circle with red line (right
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then plated for iPSC emergence (‘‘infect expanded blasts’’) (Fig-
ure 2A). In this second scenario, once mice achieved 5%–10% PB
engraftment with MLL-AF4+ blasts, they were divided into three
groups: (1) untreated, (2) treated with a Dot1L inhibitor (iDoT1L),
or (3) treated with decitabine (both at 2.5 mg/kg, subcutaneously,
for 3 days). Three days later, mice were killed and blasts were puri-
fied frombonemarrow and PB forOKSM-SeV infection (Figure 2A).
Chemicals
Information about the compounds used for enhancing reprogram-
ming, their concentration, biological function, and suppliers is
detailed in Table S3.
FISH Studies
FISHwas performedon leukemic blasts at disease presentation, and
on patient-derived iPSCs as described (Bueno et al., 2009; Menen-
dez et al., 2009) using commercially available probes (Vysis). ETV6-
RUNX1 and MLL-AF4 fusions were detected using locus-specific
LSI Dual Color Translocation probes. MLL-EPS15 and MLL-AF4 re-
arrangements were analyzed using the LSI MLL Dual Color Break
Apart Rearrangement Probe. At least 500 nuclei were analyzed.
The slides were analyzed under a fluorescence microscope equip-
ped with appropriate filters using ISIS software (Metasystems).
Gene Expression Profiling
Profilingwas performed on FACS-purified (purity >98%)MLL-AF4+
blasts from infant B-ALL (n = 3), CB-derived CD34+CD38CD19
CD33 HSCs (n = 2), CD34+CD19+CD33 B cell HPCs (n = 2),
and CD34+CD33+CD19 myeloid HPCs (n = 2). Technical dupli-
cates were performed for each independent sample. Microarray
data have been deposited in the NCBI Gene Expression Omnibus
(GSE79450). Microarrays, statistical analysis, hierarchical clus-
tering, and GO analysis were performed as detailed elsewhere (Iri-
zarry et al., 2003; Tusher et al., 2001).
Bisulfite Pyrosequencing, Human Methylation 450
BeadChip Array, and Data Analysis
Differences in global DNA methylation were compared between
MLL-AF4+ blasts and healthy CD34+CD19+ B cell HPCs and in B
cell lines before and after decitabine treatment by bisulfite pyrose-
quencing of LINE-1 elements using the EZ DNAMethylation-GoldFigure 5. DNA Methylation Differences Observed in MLL-AF4+
CD34+CD19+ B Cell HPCs
(A) Global DNA methylation analysis by pyrosequencing of LINE-1 elem
independent experiments). Error bars indicate SD.
(B) Unsupervised hierarchical clustering and heatmap showing the Cp
versus normal CD34+CD19+ B cell HPCs and CD34+ cells expressing ectop
to 1 (yellow).
(C) Venn diagrams showing the number of CpG sites differentially hy
versus normal CD34+CD19+ B cell HPCs and CD34+ ectopically express
(D) Selection of GO terms from the top 50 statistically significant bio
hypomethylated (left) or hypermethylated (right) in MLL-AF4+ blast
pressing MLL-AF4. The y axis indicates the relative risk (±95% confiden
of the proportion of genes belonging to a given GO term in a selected s
genes.kit (Zymo Research). PCR amplification of modified DNA was per-
formed using a set of primers reported previously (Bollati et al.,
2007; Ramos-Mejia et al., 2012a, 2012b). Microarray-based DNA
methylation profiling was performed with the Illumina Infinium
HumanMethylation450 BeadChip as described elsewhere (Bibi-
kova et al., 2011; Heinz et al., 2010).
Further detailed information is provided in Supplemental Exper-
imental Procedures.
ACCESSION NUMBERS
Microarray data have been deposited in NCBI Gene Expression
Omnibus (GEO: GSE79450).
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